GE HealthCare and Mass General Brigham Expanded AI Partnership

The partners have launched a project to develop generative AI tools for the field of radiation oncology.

Updated on Sept. 28, 2026 in Artificial Intelligence

Isometric editorial illustration of a sculptural radiation therapy applicator component on a clinical surface, representing medical technology development. — GE HealthCare and Mass General Brigham have expanded their research partnership to develop generative AI tools for oncology treatment planning and data synthesis. AI Illustration. Upload story photo >

Live Poll

Does the use of generative AI in medical diagnosis and treatment increase your trust in healthcare?

GE HealthCare has expanded its research collaboration with Boston-based Mass General Brigham. The two organizations aim to create new generative AI capabilities for radiation oncology workflows.

Why it matters

This initiative seeks to improve how oncology teams access and interpret complex treatment data. By simplifying information synthesis, the platform intends to streamline clinical decision-making processes.

The proposed generative AI tool will aggregate structured clinical data and unstructured information, including medical images, clinical notes, and treatment plans. This architecture aims to inform future capabilities across MR, CT, and theranostics platforms.

The players

GE HealthCare

This is a global medical technology company that provides healthcare solutions and specializes in diagnostic imaging and clinical software.

Mass General Brigham

This is a non-profit healthcare system based in Massachusetts that includes Massachusetts General Hospital and focuses on medical research and patient care.

The details

The project builds on previous technology developed by the entities and currently integrated into existing Intelligent Radiation Therapy software. The new generative AI tools will focus on helping clinicians better synthesize patient information during the treatment planning phase.

September 28, 2026: Announcement of the expanded research collaboration.

Healthcare
Sept. 28
GuideAI Health Renewed vRad Data Partnership
Artificial Intelligence
Sept. 24
Leaders Debated Hospital AI Disclosure Standards
Cancer
Sept. 23
ITM and Lumara Bio Will Present Cancer Study Data

The Tech Race

The development of this generative AI tool follows a broader industry trend of integrating advanced machine learning into clinical workflows to replace manual data synthesis. It positions the partners to maintain a competitive advantage in the specialized market for oncology information systems.

For oncology patients, this research could eventually lead to more efficient and accurate treatment planning by their care teams. While the tool is currently in development, the resulting software is intended to reduce the administrative burden on clinical staff during radiation therapy.

The takeaway

The move underscores the growing role of generative AI in translating complex medical data into actionable clinical insights. Teams looking to implement similar technologies should prioritize the integration of structured and unstructured data sources to maximize utility.